Nicotinamide Mononucleotide

ID: nicotinamide_mononucleotide

Aliases: NMN, beta-NMN, beta-nicotinamide mononucleotide

Type: compound

Route/form: oral supplement in published human trials

Status: supplement_or_investigational_context_dependent

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, review/regulatory

Source types: human_rct, review

Linked sources: 4

Broad outcomes: Fat loss / metabolic health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• NAD+ intermediate
• NAD salvage metabolism
• NMNAT conversion to NAD+
• muscle insulin-signaling hypothesis

Optimization domains

• NAD metabolism
• aging
• mitochondrial
• metabolic
• insulin sensitivity
• exercise performance
• muscle

Research basis

• NMN has human RCT signals for muscle insulin sensitivity in prediabetic women, aerobic-capacity endpoints in amateur runners, and short-term healthy-adult tolerability/NAD biomarker effects.
• It is relevant to performance discussions because the runner trial is closer to an exercise endpoint than many NAD-precursor papers.
• Best supported claim is context-specific NAD-pathway modulation, not global rejuvenation.

Limits, risks, and missing evidence

• Signals are population-, dose-, and endpoint-specific; they should not be generalized to proven anti-aging, cognition, or physique benefit.
• Regulatory status, purity, and long-term NAD-pathway tradeoffs remain important.
• Whole-blood NAD movement is not automatically tissue rejuvenation.

Risk flags

• supplement or investigational
• human rct
• clinical outcome uncertain
• nad pathway

Linked papers, labels, and reviews

1. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
   human_rct / pubmed_nmn_insulin_sensitivity_2021
   Science RCT in postmenopausal overweight/obese women with prediabetes; direct NMN insulin-sensitivity source with narrow population scope.
2. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
   human_rct / pubmed_nmn_runners_2021
   Human exercise-training NMN trial in amateur runners; supports aerobic-capacity endpoints, not broad anti-aging claims.
3. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults
   human_rct / pmc_nmn_middle_aged_2022
   Randomized multicenter dose-ranging NMN trial in healthy middle-aged adults; supports blood NAD and short-term safety/functional endpoints.
4. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
   review / pubmed_nad_boosting_molecules_review_2018
   Broad NAD-boosting review covering NR, NMN, CD38, PARP, sirtuins, aging, metabolic disease, and translational caveats.